Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06468553

Multidisciplinary Care for Lifestyle Change for Metabolic Control and Quality of Life in Prediabetes (PreCPro)

Prediabetes is part of the natural history of type 2 diabetes mellitus, which is one of the main causes of morbidity and mortality in Mexico. It is known that overweight and obesity are the main risk factors for producing insulin resistance and this in turn leads to prediabetes-diabetes mellitus 2, acting alone or together, excess adipose tissue, mainly visceral, and Prediabetes increase cardiovascular risk before hyperglycemia occurs in the diagnostic criteria for diabetes. Effective strategies have been developed focused on changing lifestyle habits (changes in dietary patterns and increased physical activity) to promote weight loss in populations with and without glucose alterations present, but with limitations in the scope for the size of the affected population. There is a small number of studies developed for this purpose, focused on a multidisciplinary intervention in low- and middle-income countries. The prediabetes care program (PreCPro) is a care initiative developed by the primary care public health services of the Government of Mexico City (CDMX) to promote weight reduction and reduction of hyperglycemia through a intervention composed of an interdisciplinary care team, centered on the patient with a focus on promoting change in people's behavior to adopt healthy eating and physical activity habits. The target population of the prediabetes care program (PreCPro) is made up of patients with prediabetes, without advanced diseases, who receive regular care in public primary care services in Mexico City.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Clinica Especializada en el Manejo de la Diabetes

Mexico City, Iztapalapa, 09060, Mexico

Location status: Recruiting

Location contact

Ruben Silva-Tinoco, MD

CONTACT

[email protected]

50381700 ext. 6690

Viridiana De la Torre-Saldaña, MD

CONTACT

[email protected]

50381700 ext. 6699

About this study

Prediabetes is part of a continuum of progressive dysglycemia that is identified with the presence of hyperglycemia resulting from the destruction or dysfunction of β cells that progresses until plasma glucose concentrations are in the range of diabetes mellitus, by which time the condition has already been detected. presence of organ damage that can no longer be fully reversed and subsequently results in increased disability, morbidity and mortality for families and the high cost of treatment for national healthcare systems. The treatment established for the prevention of diabetes mellitus 2 from stages identifiable through the diagnosis of prediabetes focuses on promoting behavioral changes for the adoption of a healthy diet and increased physical activity with the aim of producing weight reduction with consequent remission of the hyperglycemic state. Although effective behavioral programs have been created for this purpose, the best known being the Diabetes Prevention Program (DPP) in the United States and which is part of its national care strategy, similar care has been carried out in low- and middle-income countries with limited scope because it only focuses on small research studies. The barriers to the implementation of this type of care programs are usually lack of financial resources on the part of health institutions, difficulty in adapting established programs to the specific sociocultural characteristics of each population, lack of access to these programs either due to lack of of time or difficulties in attending due to distance on the part of the participants, among others. Weight loss through changes in dietary patterns and increased physical activity has been shown to prevent or delay the progression of prediabetes to diabetes mellitus 2. The PreCPro program is a care initiative developed by the public health services of primary care of the Government of Mexico City based on the pillars (diet and physical activity) recommended by national and international diabetes mellitus prevention guidelines. The target population of the PreCPro program is made up of patients with prediabetes without advanced diseases, who receive regular care in public primary care services in Mexico City.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Having diagnosis of prediabetes
  • Acceptance for participation in the program by signing informed consent sheet

Exclusion criteria

  • Any type of diabetes
  • Advanced diseases such as ischemic heart disease, heart failure, KDOQI renal failure ≥1, cerebral vascular disease with functional sequelae or those who have comorbidities that limit their life expectancy such as malignant tumors in advanced stages
  • Dependence of illicit drugs
  • Conditions that require short-term surgical treatment.
  • Pregnancy
  • Advanced cognitive deficit or serious psychiatric disorders that hinder treatment adherence
  • Use of medications whose use is associated with alterations in blood glucose levels or weight gain or loss, e.g. e.g. metformin, Glucagon-like peptide-1 receptor agonists, orlistat or corticosteroids
  • Actively taking any supplements dietary or under naturopathic, homeopathic or alternative therapies
  • Have any type of bariatric surgery procedure or weight loss device
  • Current participation in another lifestyle, behavior change, or weight loss or gain program or research study

Treatment and study plan

Prediabetes Care Program

Behavioral

Patients are cared for by the medical, nutritionist and psychology team, in a total of 14 individual and group visits, during 12 months of care. The intervention has an initial stage lasting 6 months in which 12 visits will be scheduled and a transition stage lasting 6 more months in which 2 more visits will be scheduled. Patients will be evaluated at 6 months, 12 months and 24 months

Other names: PreCPro

Primary outcomes

  1. Glycemic control after the initial stage of the program

    Time frame: six months

    HbA1c (percentage): HbA1c will be compared from the first visit with the visit six months later

  2. Change in weight after the initial stage of the program

    Time frame: six months

    Weight in kilograms. Weight will be compared from the first visit with the visit to six months later

Secondary outcomes

  1. Glycemic control

    Time frame: twenty four months

    HbA1c (percentage): HbA1c will be compared from the last visit (twelve months) and the 24-month visit

  2. Weight change

    Time frame: twenty four months

    Weight change (kg) will be compared from the last visit (twelve months) and the 24-month visit

  3. Lipid control

    Time frame: twenty four months

    Total Cholesterol, HDL-Cholesterol, Non-HDL Cholesterol and triglycerides in mg/dL will be compared from the last visit (twelve months) and the 24-month visit

  4. Blood pressure

    Time frame: twenty four months

    Systolic and diastolic blood pressure (mmHg) will be compared from the last visit (twelve months) and the 24-month visit

  5. Health-related Quality of Life perception assessed by EuroQol (EQ-5D) Visual Analogue Scale questionnaire

    Time frame: twenty four months

    Health-related Quality of life perception with EQ-5D questionnaire visual analogue scale (0-100, higher score means better self-care). Health-related Quality of Life will be compared from the last visit (twelve months) and the 24-month visit

  6. Glycemic control

    Time frame: twelve months

    HbA1c (percentage): HbA1c will be compared from the visit on the six months with the last visit (12 month)

  7. Weight change

    Time frame: twelve months

    Weight Change in kilograms will be compared from the visit on the six months with the last visit (12 month)

  8. Lipid control

    Time frame: twelve months

    Total Cholesterol, HDL-Cholesterol, Non-HDL Cholesterol and triglycerides in mg/dL will be compared from the visit on the six months with the last visit (12 month)

  9. Blood pressure

    Time frame: twelve months

    Systolic and diastolic blood pressure (mmHg) will be compared from the visit on the six months with the last visit (12 month)

  10. Health-related Quality of Life perception assessed by EuroQol (EQ-5D) Visual Analogue Scale questionnaire

    Time frame: twelve months

    Health-related Quality of life perception with EQ-5D questionnaire visual analogue scale (0-100, higher score means better self-care). Health-related Quality of Life will be compared from the visit on the six months with the last visit (12 month)

  11. Lipid control

    Time frame: six months

    Total Cholesterol, HDL-Cholesterol, Non-HDL Cholesterol and triglycerides in mg/dL will be compared from the first visit with the visit to six months late

  12. Blood pressure

    Time frame: six months

    Systolic and diastolic blood pressure (mmHg) will be compared from the first visit with the visit to six months later

  13. Health-related Quality of Life perception assessed by EuroQol (EQ-5D) Visual Analogue Scale questionnaire

    Time frame: six months

    Health-related Quality of life perception with EQ-5D questionnaire visual analogue scale (0-100, higher score means better self-care). Health-related Quality of Life will be compared from the first visit with the visit to six months later

Study contacts

Contact information is provided by the study sponsor or research team.

Ruben Silva-Tinoco, MD

CONTACT

[email protected]

50381700 ext. 6690

Viridiana De la Torre-Saldaña, MD

CONTACT

[email protected]

50381700 ext. 6699

Sponsors and collaborators

Lead sponsor

Clinica Especializada en el Manejo de la Diabetes en la Ciudad de Mexico

Network

Registry information

Official study title

Impact of a Multidisciplinary Care Program for Lifestyle Change for Metabolic Control and Quality of Life in Prediabetes: Prediabetes Care Program of Mexico City

Acronym: PreCPro

Important dates

Study start
2023
Primary completion
2025
Study completion
2027
First posted
Jun 21, 2024
Registry last updated
Jun 21, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.